Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Caprion wins $12.9 million biomarker research contract from NIAID
Under the contract to be performed over a five-year period, Caprion will act as one of two National Institute of Allergy and Infectious Diseases (NIAID) Clinical Proteomics Centers
Under the contract to be performed over a five-year period, Caprion will act as one of two National Institute of Allergy and Infectious Diseases (NIAID) Clinical Proteomics Centers
The company has greatly valued Dr Zhang’s contribution as a director of the company for the past few years.
Following the FDA advisory committee vote that there was substantial evidence of efficacy of Provenge and that Provenge was reasonably safe, the FDA requested additional clinical data to
It is anticipated that the four products will launch in January 2009, and T Lynn Mitchell Companies (TLMC), with the execution of this agreement, placed an initial order
Under the terms of the agreement, Oncalis receives a family of compounds targeting different forms of PI3-kinase (PI3-K). PI3-K is an enzyme known to be important in cancer
Approximately 24 healthy postmenopausal women have been enrolled in the study, which is designed to assess product safety and measure parathyroid hormone (PTH) blood levels at varying doses.
There were no new or unexpected safety signals reported in the study. An independent review of the primary endpoint is being conducted for US regulatory purposes. REACH is
While there was a trend in favor of Synavive, and an observed dose-response relationship, the combination did not demonstrate statistical significance compared to placebo for WOMAC question #1
Dr Smith will be responsible for all investor relations functions and will report directly to CFO, Kurt Leutzinger. Most recently, Dr Smith was a vice president and senior
MedX’s distribution partner, Technology4Medicine, a laser company in San Clemente, California will begin immediate distribution of Oralase to dental offices in the US. Oralase is a photobiomodulation device,